Food giant Mondelez is once again exploring an acquisition of chocolate maker Hershey, according to Bloomberg.

Costco Wholesale is scheduled to report earnings for the first quarter of fiscal 2025 after the market closes, with analysts expecting the retailer to report rising revenue and profits.

The S&P 500 is expected to end 2025 at a 7,100 level, suggesting a roughly 17% upside from Friday's

Palantir Technologies shares retreated Monday after hitting their latest all-time high earlier in the session.

Jefferies has upgraded Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), citing the company’s robust cystic fibrosis base business and the additional upside from the new LNP/ mRNA therapy (around $1 billion opportunity) and “triple pill” regimens. The company’s pipeline can potentially exceed expectations if the data is positive. The analyst views the risk/reward balance as mostly neutral for 2024. The pain program stands out as a potential blockbuster, especially with the upcoming launch for acute pai

JP Morgan analyst Harlan Sur maintained an Overweight rating on Broadcom Inc (NASDAQ:AVGO) with a price target of $210. Broadcom will report fiscal fourth-quarter 2024 earnings on Thursday. Sur noted a strong demand profile for AI products, continued cyclical recovery in its diversified semiconductor (ex-AI) end markets, and unlocked VMWare revenue synergy. As a result, the analyst expects revenue, earnings, and free cash flow to be better than JP Morgan and consensus expectations (revenues comi

Chinese device and now EV-maker Xiaomi revealed its latest offering in the ultra-competitive Chinese auto market, doubling down on the success it's already achieved with its SU7 EV sedan.

The key drivers of the market growth include technological advancements and a rising geriatric population, among others.

U.S. equities were down at midday, pulled lower by falling tech stocks.

On Sunday, Cogent Biosciences, Inc. (NASDAQ:COGT) revealed updated clinical results from the Open Label Extension (OLE) portion of the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis. Non-advanced systemic mastocytosis is a rare disease that involves mast cell buildup in tissues and organs. Updated clinical data presented at the American Society of Hematology Annual Meeting & Exposition show: 56% mean improvement in Total Symptom Score (TSS) at 24 weeks. 76% of